Submission |
Mar. 25, 2026 |
|---|---|
| Submission [Line Items] | |
| Central Index Key | 0001708599 |
| Registrant Name | Serina Therapeutics, Inc. |
| Form Type | S-8 |
| Submission Type | S-8 |
| Fee Exhibit Type | EX-FILING FEES |
Offerings - Offering: 1 |
Mar. 25, 2026
USD ($)
shares
|
|---|---|
| Offering: | |
| Fee Previously Paid | false |
| Other Rule | true |
| Security Type | Equity |
| Security Class Title | Common Stock, par value $0.0001 per share |
| Amount Registered | shares | 535,478 |
| Proposed Maximum Offering Price per Unit | 2.99 |
| Maximum Aggregate Offering Price | $ 1,601,079.22 |
| Fee Rate | 0.01381% |
| Amount of Registration Fee | $ 221.11 |
| Offering Note | (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional securities that may be offered or issued pursuant to the Serina Therapeutics, Inc. 2024 Equity Incentive Plan (the "2024 Plan") as a result of adjustments for stock dividends, stock splits or similar transactions effected without receipt of consideration, that increase the number of outstanding shares of the common stock, par value $0.0001 per share (the "Common Stock") of Serina Therapeutics, Inc. (the "Company"). (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) of the Securities Act, based upon the average of the high and low sales prices of the Common Stock on the NYSE American on March 23, 2026. (3) The Company is registering 535,478 shares of Common Stock relating to the 2024 Plan. Pursuant to General Instruction E to Form S-8, the fee set forth in the table above is only with respect to those additional shares. |
Fees Summary |
Mar. 25, 2026
USD ($)
|
|---|---|
| Fees Summary [Line Items] | |
| Total Offering | $ 1,601,079.22 |
| Total Fee Amount | 221.11 |
| Total Offset Amount | 0.00 |
| Net Fee | $ 221.11 |
| Offering Table N/A | |
| Offset Table N/A | N/A |